MERCK KGAA O.N./ DE0006599905 /
2024-03-28 10:02:37 AM | Chg. +2.800 | Volume | Bid10:03:00 AM | Ask10:03:00 AM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
162.500EUR | +1.75% | 1,891 Turnover: 304,582.950 |
162.600Bid Size: 250 | 162.700Ask Size: 200 | 20.68 bill.EUR | 1.38% | 24.65 |
GlobeNewswire
8:00 AM
Intravacc and Primrose Bio Announce Partnership to Enhance Conjugate Vaccine Development
GlobeNewswire
03-27
Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financi...
GlobeNewswire
03-27
Algernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program ...
GlobeNewswire
03-27
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regula...
GlobeNewswire
03-27
PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results
GlobeNewswire
03-04
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Ger...
GlobeNewswire
2023-12-21
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac ...
GlobeNewswire
2023-12-14
ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development an...
GlobeNewswire
2023-10-17
ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA